Herceptin and the Heart — A Molecular Modifier of Cardiac Failure
- 23 February 2006
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (8) , 789-790
- https://doi.org/10.1056/nejmp058315
Abstract
Translation, translation, translation. Around the halls of academic medicine, translation is the mantra of the moment. In the literary world, translation is the process of interpreting an extant body of written work and converting it into a new language. In the scientific world, translation is the application of fundamental discoveries in basic science to clinical medicine, with the goal of developing new treatments for debilitating diseases.In this arena, the development of a humanized monoclonal antibody against the HER2 protein (trastuzumab, or Herceptin) as adjuvant therapy for early HER2-positive breast cancer ranks as one of the most satisfying and powerful . . .Keywords
This publication has 3 references indexed in Scilit:
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- ErbB2 is essential in the prevention of dilated cardiomyopathyNature Medicine, 2002
- Stress Pathways and Heart FailureCell, 1999